Compare Incyte Corporation (INCY) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ING Groep NV — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.99B), while ING Groep NV trades at $33.15 (market cap $96.81B). The key difference: ING Groep NV is far larger — about 4.2× Incyte Corporation's market cap, and ING Groep NV pays a 3.9% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and ING Groep NV for 93 Days on average.
| INCY | ING | |
|---|---|---|
Market Cap | $22.99B | $96.81B |
Volume | 1,274,487 | 2,635,505 |
Sector | Health | Financials |
52-Week High | $129.93 | $37.27 |
52-Week Low | $83.80 | $23.66 |
Typical Hold Time | 33 Days | 93 Days |
Enterprise Value | $18.50B | $236.31B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
ING trades at $33.92, down 2.81% on the day, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $22.90 billion in 2025, with net income of $6.33 billion and a net margin of 28.34%. Recent earnings beats and a raised 2027 ROE target above 16% highlight operational strength, though cash flow trends show persistent net outflows.
The outlook is mixed: strong profitability and analyst consensus (64.71% buy ratings) support upside, but bearish technicals and regulatory scrutiny in Australia pose risks. Valuation appears reasonable with a P/E of 13.09, offering a potential entry for long-term investors focused on execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
